Myla Lai-Goldman

Title: Myla Lai-Goldman: Innovator in Cancer Research

Introduction

Myla Lai-Goldman is a prominent inventor based in Durham, NC (US), known for her significant contributions to cancer research. With a total of 9 patents, she has made remarkable strides in the field of oncology, particularly in the subtyping of various cancers.

Latest Patents

Among her latest patents are innovative methods for subtyping bladder cancer. These methods and compositions allow for the determination of a subtype of Muscle Invasive Bladder Cancer (MIBC) in individuals by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for MIBC. Additionally, her work includes methods for determining the response of individuals with a MIBC subtype to therapies such as immunotherapy. Another significant patent focuses on lung adenocarcinoma, providing methods and compositions for determining a subtype of lung adenocarcinoma (AD) by detecting the expression level of classifier biomarkers. This also includes methods for assessing the response of individuals with adenocarcinoma subtypes to immunotherapy.

Career Highlights

Myla has worked with esteemed institutions such as the University of North Carolina at Chapel Hill and Genecentric Therapeutics, Inc. Her work has been pivotal in advancing the understanding and treatment of cancer, particularly through the development of targeted therapies.

Collaborations

Myla has collaborated with notable colleagues, including Hawazin Faruki and Charles M Perou, contributing to a rich environment of innovation and research in cancer treatment.

Conclusion

Myla Lai-Goldman stands out as a leading inventor in cancer research, with her patents paving the way for advancements in the diagnosis and treatment of various cancer subtypes. Her work continues to impact the field significantly.